Page 83 - Read Online

Cordero et al. Bioresorbable scaffolds in acute coronary syndrome

(A Randomized Comparison of a Zotarolimus-Eluting Stent With an 2016;134:1708-19.
Everolimus-Eluting Stent for Percutaneous Coronary Intervention). J 36. Brugaletta S, Gori T, Low AF, Tousek P, Pinar E, Gomez-Lara J,
Am Coll Cardiol 2014;63:1617-25. Scalone G, Schulz E, Chan MY, Kocka V, Hurtado J, Gomez-
29. Tada T, Kadota K, Hosogi S, Miyake K, Ohya M, Amano H, Izawa Y, Hospital JA, Münzel T, Lee CH, Cequier A, Valdés M, Widimsky P,
Kanazawa T, Kubo S, Ichinohe T, Hyoudou Y, Hayakawa Y, Sabbah Serruys PW, Sabaté M. Absorb bioresorbable vascular scaffold versus
MM, Otsuru S, Hasegawa D, Habara S, Tanaka H, Fuku Y, Katoh everolimus-eluting metallic stent in ST-segment elevation myocardial
H, Goto T, Mitsudo K. Association between tissue characteristics infarction: 1-year results of a propensity score matching comparison:
assessed with optical coherence tomography and mid-term results the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a
after percutaneous coronary intervention for in-stent restenosis clinical evaluation of everolimus eluting coronary stents in the
lesions: a comparison between balloon angioplasty, paclitaxel-coated treatment of patients with ST-segment elevation myocardial
balloon dilatation, and drug-eluting stent implantation. Eur Heart J infarction). JACC Cardiovasc Interv 2015;8:189-97.
Cardiovasc Imaging 2015;16:1101-11. 37. Sabaté M, Windecker S, Iñiguez A, Okkels-Jensen L, Cequier A,
30. Stone GW, Gao R, Kimura T, Kereiakes DJ, Ellis SG, Onuma Y, Brugaletta S, Hofma SH, Räber L, Christiansen EH, Suttorp M,
Cheong WF, Jones-McMeans J, Su X, Zhang Z, Serruys PW. 1-year Pilgrim T, Anne van Es G, Sotomi Y, García-García HM, Onuma
outcomes with the Absorb bioresorbable scaffold in patients with Y, Serruys PW. Everolimus-eluting bioresorbable stent vs. durable
coronary artery disease: a patient-level, pooled meta-analysis. Lancet polymer everolimus-eluting metallic stent in patients with ST-
2016;387:1277-89. segment elevation myocardial infarction: results of the randomized
31. Lane JP, Perkins LE, Sheehy AJ, Pacheco EJ, Frie MP, Lambert BJ, ABSORB ST-segment elevation myocardial infarction-TROFI II
Rapoza RJ, Virmani R. Lumen gain and restoration of pulsatility after trial. Eur Heart J 2016;37:229-40.
implantation of a bioresorbable vascular scaffold in porcine coronary 38. Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, Caramanno
arteries. JACC Cardiovasc Interv 2014;7:688-95. G, Naber C, Di Mario C, Colombo A, Capranzano P, Wiebe J,
32. de la Torre-Hernández JM, Alfonso F, Hernández F, Elizaga J, Araszkiewicz A, Geraci S, Pyxaras S, Mattesini A, Naganuma T,
Sanmartin M, Pinar E, Lozano I, Vazquez JM, Botas J, Perez de PA, Münzel T, Tamburino C. Percutaneous coronary intervention with
Hernández JM, Sanchis J, Nodar JM, Gomez-Jaume A, Larman M, everolimus-eluting bioresorbable vascular scaffolds in routine clinical
Diarte JA, Rodríguez-Collado J, Rumoroso JR, Lopez-Minguez JR, practice: early and midterm outcomes from the European multicentre
Mauri J; ESTROFA Study Group. Drug-eluting stent thrombosis: GHOST-EU registry. EuroIntervention 2015;10:1144-53.
results from the multicenter Spanish registry ESTROFA (Estudio 39. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.
ESpanol sobre TROmbosis de stents FArmacoactivos). J Am Coll 40. Andrés E, Cordero A, Magán P, Alegría E, León M, Luengo E, Botaya
Cardiol 2008;51:986-90. RM, García Ortiz L, Casasnovas JA. Long-term mortality and hospital
33. Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, Ariti readmission after acute myocardial infarction: an eight-year follow-up
C, Litherland C, Dangas G, Gibson CM, Krucoff MW, Moliterno study. Rev Esp Cardiol 2012;65:414-20.
DJ, Kirtane AJ, Stone GW, Colombo A, Chieffo A, Kini AS, 41. Rogers JK, Yaroshinsky A, Pocock SJ, Stokar D, Pogoda J. Analysis
Witzenbichler B, Weisz G, Steg PG, Pocock S. Coronary thrombosis of recurrent events with an associated informative dropout time:
and major bleeding after PCI with drug-eluting stents: risk scores application of the joint frailty model. Stat Med 2016;35:2195-205.
from PARIS. J Am Coll Cardiol 2016;67:2224-34. 42. Sedlis SP, Hartigan PM, Teo KK, Maron DJ, Spertus JA, Mancini GB,
34. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, Gold Kostuk W, Chaitman BR, Berman D, Lorin JD, Dada M, Weintraub
HK, Burke AP, Kolodgie FD, Virmani R. Delayed arterial healing and WS, Boden WE; COURAGE Trial Investigators. Effect of PCI on
increased late stent thrombosis at culprit sites after drug-eluting stent long-term survival in patients with stable ischemic heart disease. N
placement for acute myocardial infarction patients: an autopsy study. Engl J Med 2015;373:1937-46.
Circulation 2008;118:1138-45. 43. Cordero A, Carrillo P, López-Palop R. Letter by Cordero et al
35. Vilahur G, Gutierrez M, Casani L, Varela L, Capdevila A, Pons- regarding article, “Regional systems of care demonstration project:
Llado G, Carreras F, Carlsson L, Hidalgo A, Badimon L. Protective American Heart Association Mission: Lifeline STEMI Systems
effects of ticagrelor on myocardial injury after infarction. Circulation Accelerator”. Circulation 2016;134:e700-1.

76 Vessel Plus ¦ Volume 1 ¦ June 27, 2017